Cancer API Market Research Report Information by Drug Type (Innovative Oncology API, And Generic Oncology API), By Manufacturer Type (Captive Manufacturer, Merchant Manufacturer), By Type Of Synthesis (Synthetic Oncology Apis, And Biotech Oncology API), By Indication (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Stomach Cancer, Liver Cancer, Cervical Cancer, And Others), and by Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2032

Global Cancer API Market Overview

Cancer API Market size was valued at USD 43.9 billion in 2022. The Cancer API Market industry is projected to grow from USD 46.1 billion in 2023 to USD 76.3 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.88% during the forecast period (2023 - 2032).

The factors contributing to the growth of the market are the increasing demand for newly developed small molecule drugs and rising prevalence of cancer.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Cancer API Market Trends

•  increasing demand for newly developed small molecule drugs

The increasing demand for newly developed small molecule drugs is a significant driver in the Cancer API Market. Small-molecule drugs play a vital role in cancer treatment, and there is a continuous need for new and innovative therapeutic options. The development of small-molecule drugs allows for targeted approaches to cancer treatment, enabling precise interactions with specific molecular targets involved in the progression of the disease. The demand for these newly developed small molecule drugs drives the market for cancer APIs. In addition, small molecule drugs have high potency and efficacy in inhibiting specific molecular targets involved in cancer progression. Their wide applicability across various cancer types, formulation flexibility, and the opportunity for intellectual property protection incentivize their development. Hence, small-molecule drugs are leading the drug market and have attained the highest number of drug approvals in the past couple of years. There has been a significant development in small molecule API manufacturing in oncology. Overall, the demand for newly developed small-molecule drugs plays a crucial role in advancing cancer treatment options and propelling the growth of the cancer API market.

The increasing prevalence of cancer is a significant driver for the Cancer API Market. Cancer remains a major global health concern, with a rising incidence observed across different regions and populations. For instance, according to the World Health Organization (WHO), cancer is one of the leading causes of morbidity and mortality worldwide, accounting for an estimated 10 million deaths in 2020. The incidence of cancer is influenced by various factors, including population growth, aging demographics, lifestyle changes, environmental exposures, and genetic predisposition. In addition, as per the International Agency for Research on Cancer (IARC) reported that the global cancer burden is projected to increase to 28.4 million new cancer cases by 2040. Similarly, according to the American Cancer Society, In the US, there were approximately 1.9 million new cancer cases and nearly 609,360 cancer-related deaths in 2022.

Therefore, the increasing demand for newly developed small molecule drugs, the rising prevalence of cancer, and the growing trend of pharmaceutical outsourcing industry are fueling market growth.

Cancer API Market Segment Insights

Cancer API Drug Type Insights

Based on drug type, the Cancer API Market has been segmented into innovative oncology APIs and generic oncology APIs. Innovative oncology APIs, also known as branded APIs, segment is the largest segment owing to their ability to provide a groundbreaking solution for diseases including cancer, which is considered one of the most difficult conditions to treat. Innovative oncology APIs are highly costly; however, innovation-based development drugs are highly in demand due to their high safety & efficacy and assist manufacturers in generating a high level of revenue.

Cancer API Manufacturer Type Insights

Based on manufacturer type, the Cancer API Market has been segmented into captive manufacturers and merchant manufacturers.

The captive manufacturers segment is the largest and fastest growing segment during the forecast period owing to high demand of APIs both generic and branded drugs for the consumption of the finished drug forms (FDF) portfolio. Moreover, captive manufacturer includes Dr. Reddy’s Laboratories (India), Biocon (India), Medicamen Biotech Limited (India) have drug master files (DMFs) for major countries includes US, Canada, Russia, Australia, Malaysia, South Africa, China, Israel, Singapore, and others.

Cancer API Type of Synthesis Insights

The Cancer API Market, based on type of synthesis, has been segmented into synthetic oncology APIs and biotech oncology APIs.

The synthetic oncology APIs segment held the largest market share in 2022 of XX% and dominated the market during the forecast period. This is due to the higher demand for synthetic oncology APIs in the country, namely the US, and the region, including Asia-Pacific. Pharmaceutical companies are indulging in increasing the outsourcing of synthetic oncology API production and increasing approval for synthetic oncology APIs is another imperative driver.

Cancer API Indication Insights

Based on indication, Cancer API Market, has been segmented into lung cancer, breast cancer, colorectal cancer, prostate cancer, stomach cancer, liver cancer, cervical cancer, others including pancreatic cancer, thyroid cancer, and bladder cancer.

The lung cancer segment dominated the market during the forecast period, and breast cancer accounted for the fastest-growing segment during the forecast period. The factors that influence the growth of the indication segment are the increasing prevalence of cancer across the globe and the rising development of APIs to target these cancer receptors. As per the AstraZeneca PLC (UK) Annual Report 2022, cancer disease held a second rank across the globe in causing death, and by 2040, there will be 16.3 million deaths annually from cancer globally. This will create a flourishing opportunity for both captive and merchant APIs manufacturers during the forecast period.

FIGURE 2: CANCER API MARKET, BY INDICATION, 2022 & 2032 (USD BILLION)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Cancer API Regional Insights

By region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World. North America accounted for the largest market share of 47.76% in 2022 owing to the Factors such as the rising prevalence of cancer, a growing preference for personalized medicine, an increase in private and public sector funding, and rapid advancements in cancer technologies are driving the market for cancer APIs in the North America region. Furthermore, according to United States Cancer Statistics, in the US in 2019, there were 1,752,735 new cancer cases recorded and 599,589 cancer deaths. There were 439 new cancer cases recorded for every 100,000 people, and 146 individuals died from cancer.

Further, the major countries studied are: The US, Canada, Brazil, Germany, France, the UK, Italy, Spain, China, India, Japan, South Korea, Australia.

FIGURE 3: CANCER API MARKET, BY REGION, 2022 & 2032 (USD BILLION)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

The Europe cancer API market is predicted to increase significantly throughout the projection period. The market is likely to be driven by increased research funding and the local presence of major industry players in this area. The number of pharmaceutical firms in Europe is expanding as investments increase. Furthermore, countries such as the UK, Germany, France, and Italy have well-established healthcare systems and extensive research activities. Moreover, the region's commitment to preventive healthcare, as well as the increased emphasis on personalized medicine are driving demand for cancer APIs in Europe. Additionally, leading pharmaceutical businesses, academic institutions, and research organizations are in the region, supporting innovation and propelling the industry ahead. Furthermore, strict regulatory systems in Europe protect the quality and safety of cancer APIs. For instance, in March 2022, Novartis AG (Switzerland)'s subsidiary, Advanced Accelerator Applications (France), produced Lutetium (177 Lu) Vipivotide Tetraxetan, a synthetic active substance created to treat prostate-specific membrane antigen-positive castration-resistant metastatic prostate cancer. Through the development of innovative and effective cancer APIs, Europe continues to play a vital role in influencing the future of cancer therapy. Furthermore, the France Cancer API Market held the largest market share in 2022 and Germany Cancer API Market is the fastest growing market in the Europe region.

The existence of economies such as China and India, on which the world relies for low-cost API production, is advantageous to the region. Rising healthcare spending in the region is expected to drive market expansion. The rising burden of cancer cases, greater knowledge of the diseases and treatment of the early-onset cancer epidemic, and increased new products being launched are all factors contributing to market expansion. Furthermore, according to the GLOBOCAN 2020 factsheet, 1,324,413 new cancer cases were reported in India in 2020 (678,383 females and 646,030 males). Furthermore, according to the ICMR 2021 Report, the number of cancer patients in India is predicted to climb from 26.7 million in 2021 to 29.8 million in 2025. Therefore, the increasing prevalence of cancer will further help the cancer API market in the Asia-Pacific region to propel.

Cancer API Key Market Players & Competitive Insights

Major market players are spending a lot of money on R&D to increase their product, which will help the Cancer API Market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, including new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the Cancer API industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

Avra Laboratories Pvt Ltd. manufactures and supplies active pharmaceutical ingredients (API), medicinal chemicals, and botanical products. It manufactures active pharmaceutical ingredients with a focus on several therapeutic areas, including anti-cancer, anti-ulcer, anti-thrombotic, hematology, PAH, antipsychotic, and psoriatic arthritis. It also offers contract research and production services. The business also provides a variety of expertise in the synthesis of tiny molecules in low quantities that have great economic value for pharmaceutical applications, offering sophisticated intermediates to numerous domestic and foreign pharmaceutical firms. The business also has a reputable and seasoned scientific leadership team with strong client ties to significant pharma and biotech firms. It has three manufacturing facilities, two of which are in Hyderabad (one of which is a USFDA-approved facility), and one more in the Indian city of Visakhapatnam. Furthermore, Avra Laboratories Pvt Ltd. serves its customers worldwide. Moreover, Avra Laboratories Pvt Ltd has expanded the active pharmaceutical component production facility at Nacharam in the Hyderabad district of Telangana. With this expansion, the daily capacity of the production unit will rise from 100.12 kg to 158 kg.

Key Companies in the Cancer API Market includes.

• Reddy’s Laboratories Ltd


• Sun Pharmaceuticals Industries Ltd


• Beta Drugs Limited


• Axplora


• Bulat Pharmaceutical


• Avra Laboratories Pvt Ltd


• Biocon


• Teva Pharmaceutical Industries Ltd


• Bochem Pvt. Ltd


• Mac-Chem Products (India) Pvt. Ltd


• Others

Cancer API Industry Developments

May 2023 Sun Pharma entered into a license agreement with Philogen SpA (Italy) for commercializing Philogen’s specialty cancer product, Nidlegy (Daromun) in Australia, Europe, and New Zealand. As per the agreement Sun Pharma holds exclusive rights to marketing Nidlegy for skin cancer in Europe, New Zealand, and Australia.

January 2023, Dr. Reddy's Laboratories announced the acquisition trademark rights of the breast cancer drug Primcyv (Palbociclib) from Pfizer. As per the agreement company Dr.Reddy manufactured cancer API in its production facility which is approved by US FDA.

December 2021, Biocon partnered with Tabuk Pharmaceuticals (Saudi Arabia) to provide its specialty generic drugs in the Middle East. The partnership will allow Biocon access to the MENA region, which now encompasses Jordan, Lebanon, Saudi Arabia, the United Arab Emirates, Kuwait, Qatar, Oman, and Iraq

Cancer API Market Segmentation

Cancer API Drug Type Outlook

• Innovative Oncology APIs


• Generic Oncology APIs

Cancer API Manufacturer Type Outlook

• Captive Manufacturer


• Merchant Manufacturer

Cancer API Type of Synthesis Outlook

• Synthetic Oncology APIs


• Biotech Oncology APIs

Cancer API Indication Outlook

• Lung Cancer


• Breast Cancer


• Colorectal Cancer


• Prostate Cancer


• Stomach Cancer


• Liver Cancer


• Cervical Cancer


• Others

Cancer API Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • India
  
  
  • Japan
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America